Acute myeloid leukemia 2025

Acute myeloid leukemia (AML) remains one of the greatest challenges in hematology. Despite established chemotherapy protocols, the prognosis for many patients remains unfavorable. In recent years, however, new molecular classifications, refined risk stratification and the use of targeted substances have decisively changed treatment. The current overview summarizes the most important diagnostic, prognostic and therapeutic developments and provides oncologists with an evidence-based foundation for clinical practice in 2025.